Quest Diagnostics Sets Aside $32 Million For Legal Claims As Data-Breach Suits Near A Settlement

Reserves for legal matters rose from $20 million at year-end, and a second breach surfaced one day before the quarterly report.

Share
Quest Diagnostics Sets Aside $32 Million For Legal Claims As Data-Breach Suits Near A Settlement

Quest Diagnostics, the laboratory testing company, now carries $32 million in reserves for legal matters, and it says the parties in its 2019 AMCA data-breach class actions have agreed in principle to settle. The 10-Q came Friday, a day after an 8-K disclosed a new unauthorized-access incident at a client ordering system.

From discovery to a deal in principle

Legal reserves stood at $32 million on September 30, up from $20 million at year-end 2025. The quarter before, the company had reported $17 million at June 30.

The second-quarter filing described discovery and class certification in the AMCA litigation as ongoing. The new filing says instead that the parties have an agreement in principle and are drafting a definitive settlement agreement.

A previous passage on Medicaid billing inquiries from the New York Attorney General is gone. It still says the company has received several subpoenas from that office and responded. A group of state attorney general offices continues to investigate the AMCA incident, the company said, and it is cooperating.

Quest, which provides lab testing and diagnostic information to physicians, hospitals, patients, health plans and employers, says it cannot estimate a range of loss for these matters.

A second breach, one day earlier

In an 8-K filed Thursday, Quest said it learned on October 21 of unauthorized access to Quanum LSM, a system clients use to place test orders and look up results. The company has notified federal law enforcement and hired outside cybersecurity experts.

The full scope is still under investigation, but Quest said it believes an unauthorized party accessed certain patient records. It said the incident has not materially disrupted operations. The 10-Q lists the incident among risks to future results.

Receivables stretch as client payers grow

Days sales outstanding, a measure of how fast Quest collects what it bills, reached 51 days at September 30. That compares with 48 at year-end 2025 and 47 a year earlier. The filing attributes the rise to a shift toward receivables from client payers.

Client payers made up 48% of net accounts receivable, against 43% at year-end. Healthcare insurers fell to 23% from 27%.

Volume grew 14.5% in the quarter, of which 9.5% came from new work with Corewell Health and Fresenius Medical Care. Revenue per requisition fell 4.2%, which the filing ties to the mix of routine tests in those relationships.

A strong quarter underneath

The legal items sit against a quarter in which revenue rose 10.0% to $3,097 million and diluted earnings per share climbed 28.7% to $2.78, according to the company's earnings release. Quest raised its full-year revenue outlook to between $12.065 billion and $12.105 billion.

Reserves for general and professional liability claims were $180 million at September 30, against $178 million at year-end.

The next step is a definitive AMCA settlement agreement, which the parties are still drafting.

Sources

More on Quest Diagnostics

All Quest Diagnostics (DGX) coverage →